Tianjin Rianlon Chemical Co., Ltd. Overview
| Item | Detail | Source |
|---|---|---|
| Current legal name | 天津利安隆新材料股份有限公司 (Tianjin Rianlon New Materials Co., Ltd.) | H1 2026 Interim Report |
| English name | Rianlon Corporation (RC) | H1 2026 Interim Report |
| Former name | 利安隆(天津)化工有限公司 — Rianlon (Tianjin) Chemical Co., Ltd. (2003–2013) | H1 2026 Interim Report, Note III |
| Founding / incorporation date | 8 August 2003 (S&P profile states 2007 — conflicts with the company's own filing; company filing preferred) | H1 2026 Interim Report; StockAnalysis profile |
| Incorporation jurisdiction | People's Republic of China (Tianjin, TEDA) | FY2024 Annual Report |
| Unified Social Credit Code | 911,201,167,522,185,471 | H1 2026 Interim Report |
| Registered address | No. 6 Huangshan Road, Hangu Modern Industrial Zone, TEDA, Tianjin 300480 | FY2024 Annual Report |
| Head office | 20F, Block F, No. 20 Kaihua Road, Huayuan Industrial Zone, Nankai District, Tianjin 300384 | FY2024 Annual Report |
| Exchange / ticker | Shenzhen Stock Exchange, ChiNext — 300596 (short name 利安隆) | FY2024 Annual Report |
| ISIN | CNE100002MQ2 | StockAnalysis / SZSE profile |
| CUSIP | Not applicable (no US listing) | — |
| Share capital | 229,619,667 A-shares, 100% unrestricted as of 30 June 2026 | H1 2026 Interim Report |
| Fiscal year end | 31 December | FY2024 Annual Report |
| Legal representative | Fan Xiaopeng (范小鹏) — per H1 2026 report (FY2024 report listed Li Haiping) | H1 2026 Interim Report |
| Chairman & President; actual controller | Li Haiping (李海平); ~25.05% combined indirect stake | H1 2026 Interim Report; Eastmoney/Tianyancha summary (Aug 2026) |
| Auditor | Baker Tilly China (天职国际会计师事务所(特殊普通合伙)); standard unqualified opinions FY2024 (Tianzhi Ye Zi [2025] 14766) and FY2025 (Tianzhi Ye Zi [2026] 20716); auditor changed to Baker Tilly in FY2024 (predecessor auditor not named in sources reviewed) | FY2024 AR; FY2025 Audit Report |
| Employees (latest) | 3,068 (latest annual report, FY2025) | Eastmoney summary citing latest AR, Aug 2026 |
| Market capitalization | CNY 9,031 M (29 Sep 2026; close CNY 39.33 on 30 Sep 2026); EV CNY 11,150 M | S&P std. via StockAnalysis |
| Website | www.rianlon.com; IR e-mail sec@rianlon.com; tel. +86 22 8371 8775 | FY2024 AR |
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total employees (headcount) | 3,238 | 3,153 | 3,068 |
| R&D personnel | 442 | 445 | — |
Note: FY2023 total headcount is derived (442 R&D staff ÷ 13.65% R&D share, FY2024 AR); FY2024 is reported (parent 464 + main subsidiaries 2,689, FY2024 AR); FY2025 is per the latest annual report as cited by Eastmoney (Aug 2026). The FY2024 workforce split was: production 1,552; technical 870; administrative 537; sales 132; finance 62; by education 10 PhDs, 144 master's, 907 bachelor's, 2,092 diploma or below. Outsourced labour amounted to 2.70 million hours costing CNY 96.4 M in FY2024.
Rianlon is China's largest producer of polymer anti-aging additives — antioxidants (RIANOX), light stabilizers including UV absorbers and HALS (RIASORB), and customized one-pack blends (U-pack®) — and describes itself as one of only two companies globally offering a full-range anti-aging portfolio, the other implicitly being BASF. Built by a founding team from Tianjin University's chemical engineering faculty, it operates a "dual-base" supply model in which every core product is made at two or more Chinese sites. Since 2022 it has added a second growth engine in lubricant additives through Jinzhou Kangtai, positioned as a domestic substitute for the Western "big four", and incubated life-science building blocks and electronic-grade polyimide via the 2024 acquisition of Korea's IPITECH. FY2025 revenue was CNY 6.02 bn with CNY 497 M net profit. Its strategic pivot is now toward globalized capacity (Johor, Malaysia) and a partnership with Infineum.
What the company does
Rianlon manufactures specialty chemical additives that are dosed in small quantities into large-volume host materials — plastics, coatings, rubber, fibers, adhesives and lubricating oils — to protect them against thermal-oxidative, photo-oxidative and mechanical degradation. The economic logic is "small dosage, large effect": additives are a minor fraction of a customer's bill of materials but determine whether a polymer part or lubricant meets its service-life specification, which creates qualification barriers, long approval cycles and sticky customer relationships (SZSE company profile; FY2024 AR).
Company's own description (paraphrased from H1 2026 Interim Report and FY2024 AR)
The company characterizes itself as a global "chemistry and biotechnology platform" enterprise whose mission is to create a colourful life through chemistry and biology and whose ambition is a century-old Rianlon brand. Management organizes the business into three "life curves": (1) polymer anti-aging additives — described as "the rice in the pot", the cash-generative core whose goal is global top-tier status; (2) lubricant additives — "the grain in the barn", a scale business positioned as a backbone of domestic substitution; and (3) life sciences — "the rice in the field", an R&D-heavy option on the future. A fourth, separately-managed emerging line covers electronic-grade polyimide (PI) and, since late 2025, electronic adhesives. The organization runs on a "headquarters + business division" model in which each division owns R&D, production, supply chain and sales (H1 2026 Interim Report, MD&A).
Independent characterization
Rianlon is best understood as a mid-cap, vertically integrated Chinese specialty-additives producer whose earnings remain ~80% dependent on a cyclical, increasingly commoditized polymer-additive franchise, onto which management has bolted a lower-margin but faster-growing lubricant-additive business and several venture-like options. Its competitive moat rests on (a) breadth of portfolio, (b) multi-site redundancy, (c) cost position in China, and (d) long qualification histories with global polymer majors. Its weaknesses are a balance sheet that has steadily re-levered (total debt CNY 3.76 bn at FY2025 vs. CNY 1.48 bn at FY2021), structurally weak free-cash conversion, and margins well below pre-2023 levels after a domestic price war. The 2026 strategic narrative — Johor capacity, the Infineum alliance and EU/Japanese capacity retreat — is the most important swing factor for re-rating.
Business and revenue model
| Dimension | Characterization |
|---|---|
| Revenue model | ~100% product sales (B2B industrial chemicals); no subscription/licensing revenue disclosed. "Other business revenue" was CNY 18.3 M in FY2024 (0.32% of revenue) |
| Sales channel | Direct sales 91.68% (CNY 5,214.0 M) and distributors 8.32% (CNY 472.9 M) in FY2024; distribution grew 26.96% YoY (FY2024 AR) |
| Revenue recognition | Point-in-time on delivery (domestic) or customs declaration/bill of lading (export) (H1 2026 report, accounting policies) |
| Value-chain position | Mid-stream: buys petrochemical intermediates (alkylphenols, fatty alcohols/ketones, fatty acids/esters, aromatic amines, inorganics) and sells formulated or single-component additives to polymer producers, compounders, coatings makers, lubricant blenders and additive majors |
| Customer concentration | Low: top-5 customers = 13.51% of FY2024 sales (largest 4.38%); top-5 suppliers = 24.46% of purchases (FY2024 AR) |
| Customer types | Global and Chinese polymer producers and compounders, coatings/adhesive makers, fiber producers, national oil companies (Sinopec, PetroChina), international oil companies and international additive companies (lubricants), biotech/CDMO and IVD reagent makers (life sciences), flexible-display and FPC makers (PI) |
| End-markets | Automotive & transportation (incl. NEV), building & construction, agriculture films, electronics & electrical, packaging, textiles, sports & leisure, household goods, renewable energy (PV/EVA film, energy storage), personal care, healthcare, fuels & lubricants (S&P business description; FY2024 AR) |
Key raw-material exposures (FY2024 AR)
| Raw material category | Share of total purchases FY2024 (%) | H1 2024 avg price (CNY/kg) | H2 2024 avg price (CNY/kg) |
|---|---|---|---|
| Alkylphenols | 19.25 | 12.01 | 11.95 |
| Fatty ketones/alcohols | 15.71 | 8.40 | 7.42 |
| Fatty acids & esters | 8.86 | 13.32 | 13.73 |
| Inorganic compounds | 8.66 | 3.24 | 3.17 |
| Aliphatic hydrocarbons | 5.25 | 12.86 | 10.72 |
| Aromatic amines | 3.82 | 13.68 | 12.56 |
| Aliphatic thiols | 2.66 | 24.65 | 24.41 |
| Coal (CNY/t) | 1.23 | 537.68 | 480.93 |
Strategy
Stated strategy (paraphrased themes from FY2024 AR and H1 2026 report)
-
"2.0 Strategy" (set 2019) with 2028 revenue targets: New Materials Division CNY 10 bn; Lubrication Division CNY 4 bn; Life Sciences Division CNY 1 bn (FY2024 AR). Pursued through "Big 3+1 / Small 3+1" annual targets (definitions not disclosed). A "3.0 plan" for 2028 onward is under preparatory study (H1 2026 report).
-
Low cost to survive, differentiation to grow: procurement optimization, energy control, lean manufacturing, AI-driven operations; differentiation via high-barrier products (triazine UVAs, low-basicity HALS, water-dispersed and PCR-upgrade additives).
-
"Dual going-out" of R&D and capacity: Johor, Malaysia as the "bridgehead" of globalization; domestic-plus-overseas supply-chain "dual circulation".
-
Import substitution of "chokepoint" materials: lubricant additives (domestic standard D1), electronic-grade PI, electronic adhesives.
-
"Rianlon Basic Law" (H1 2026): five commitments — chemistry-plus-biology dual technology; domestic-plus-international dual markets; innovation as core engine; green/low-carbon transformation; AI-native transformation.
-
Innovation spend floor: R&D ≥ 4% of revenue annually; new Strategic Development Department for opportunity discovery.
Initiative register (last 24 months)
| Initiative | Date | Description | Quantified target / status |
|---|---|---|---|
| Malaysia R&D & production base | Announced 2025; groundbreaking 20 Jan 2026 | Via Singapore sub; up to USD 300 M; first overseas R&D centre | Phase I budget CNY 1,297.85 M; CNY 435.9 M invested, 60% progress (30 Jun 2026); 15.9 kt anti-aging capacity under construction; CNY 1.2 bn guarantee line approved |
| Infineum strategic framework agreement | 21 Jan 2026 | Rianlon component manufacturing integrated into Infineum's global supply network for China/APAC | Extended 22 Jul 2026 by Infineum–Kangtai distribution collaboration across Southern Asia |
| Yixing PI base | 2024– | Domestic PI production and R&D | Budget CNY 400 M; operation targeted 2027 |
| Stofor electronic adhesives | 27 Nov 2025 | CNY 50 M for 25% | Associate; −CNY 3.15 M share of loss H1 2026 |
| AI-native transformation | 2,026 | "Smart Rianlon Digital Platform", unified data middle-office, AI across R&D/manufacturing/supply chain/marketing | No financial target disclosed |
| Life sciences commercialization | 2024– | Shift from R&D to dual R&D/market; animal nutrition launch | Bio-building blocks break-even target FY2026 |
| Personal-care anti-aging | 2024– | Aegis acquisitions | No target disclosed |
| ESG/energy | 2,026 | Green power at 3 bases; Tianjin steam-saving project; Kaiya direct green-power supply in preparation; reserve projects in distributed PV, biomass CHP | 7 bases carbon-accounted; 27 product carbon footprints verified |
| Capital-market programmes | Jan–Feb 2025 | "Quality & Return Dual Enhancement" plan; market value management system | Commitment to stable cash dividends; no valuation-enhancement plan disclosed |
| Financing | Jan 2026 | CNY 800 M sci-tech MTN (2.10%, 3 years) | Completed |
Medium-term guidance
No numeric annual guidance is published. The only quantified medium-term targets are the 2028 divisional revenue goals (aggregate CNY 15 bn vs. FY2025 actual CNY 6.0 bn), which would require ~35% annual growth from 2026 — implausible organically and best treated as aspirational.
Products & Services
Polymer anti-aging additives (New Materials Division)
| Product family | Named products / chemistries | Function & specification highlights | Target customers | Production sites | Latest technical milestones |
|---|---|---|---|---|---|
| Primary (hindered phenolic) antioxidants | RIANOX 1010, 1076, 245, 1098, 1035, 1135 (liquid), 2135, 1520, 1726, 1790 (asymmetric), 330 (high-temperature), 1019, 3114, MD-1024 (metal deactivator), MD-697, BBM, CPL, trisphenol | Retard oxidative degradation during polymerization, processing and service life; non-organotin catalytic synthesis | Polyolefin, ABS, engineering plastics, elastomer, fiber, adhesive producers | Tianjin, Zhongwei, Zhuhai | Trisphenol process patent application CN119039111A (2024) |
| Secondary antioxidants | Phosphites incl. hydrolysis-resistant grades, thioesters (412S), alkylated diphenylamines, amide antioxidants | Hydroperoxide decomposition; synergy with phenolics | Polymer producers, lubricant and polyol makers | Tianjin, Zhongwei, Zhuhai | Hydrolysis-resistant phosphite patents ZL202011275145.4, ZL202011542259.0 |
| UV absorbers | Benzotriazoles (UV-326, 328, 1130, 360), triazines, benzophenones, phenyl benzoates, red-shifted UVA, reactive benzotriazoles | Absorb UV radiation; triazines are highest-performance class | Coatings, agriculture film, automotive, PV encapsulants | Zhongwei, Kerun, Kaiya | Three new triazine UVAs developed in 2024; red-shift UVA US patent US20250026916A1 |
| Hindered amine light stabilizers (HALS) | 944, 622, NOR-type low-basicity HALS, polymeric HALS, hydroxyl-HALS | Radical scavenging; low-basicity grades for acidic environments (agri film, high-end coatings) | Coatings, agri film, automotive plastics | Kaiya (Hengshui), Chifeng | One low-basicity HALS in mass production (2024), two in process design |
| U-pack® customized blends | Low-melting weathering masterbatches, rubber liquid antioxidants, POM/SBS/PU/PA stabilizer systems, spandex and ES fibre stabilizers, EVA film light-stabilizer packages, cable, C5 resin, polystyrene, wood-plastic, aluminium-silver paste systems | One-stop formulated solution reduces customer handling and QC cost | Compounders, OEM-specified applications | Tianjin, Zhongwei, Hengshui, Zhuhai | High-performance anti-aging masterbatch in commercial sale; PCR (post-consumer recycled) plastic upgrade packages — three developed, one in mass sales |
| Water-dispersed additives | Ultrafine-milled aqueous antioxidant dispersions | For emulsion/suspension polymers, waterborne coatings and adhesives | Latex, waterborne coatings | Tianjin (5 kt project announced 2022) | Three new products at customer evaluation (2025) |
| Regulatory-replacement products | SVHC-substitute antioxidants/stabilizers | Compliance with ECHA/REACH restrictions | EU-facing customers | — | Two substitution solutions developed |
| Polymerization inhibitors & intermediates; nylon monomers | Inhibitors; decanediamine, nylon 1010/1012 salts (Kaiya licence scope) | By-product and adjacency chemistry | Monomer producers | Hengshui, Chifeng | — |
| Personal-care anti-aging | Via Tianjin Aegis / Aegis Beauty Solutions (HK) | Extension of anti-aging chemistry into cosmetics | Personal-care brands | — | Management states entry into personal-care anti-aging is in progress (H1 2026 report) |
Pricing model: spot and contract B2B pricing; no list prices disclosed. Capacity: designed anti-aging capacity 240.7 kt with 55.65% utilization in FY2024 (FY2024 AR); 242.1 kt in place plus 19.9 kt under construction (Zhongwei 3.5 kt, Kerun 0.5 kt, Malaysia 15.9 kt) per FY2025 AR digest.
Lubricant additives (Lubrication Division — Jinzhou Kangtai)
| Product family | Content | Applications | Status |
|---|---|---|---|
| Detergents | Sulfonates, sulfurized alkylphenates (incl. high-TBN, low-free-phenol grades), alkyl salicylates | Engine and marine oils | Two high-TBN phenates in mass production; two low-free-phenol grades at pilot; four salicylates developed (FY2024 AR) |
| Dispersants | Ashless (PIB-succinimide) incl. soot-handling dispersants | Heavy-duty diesel engine oils | Soot dispersant in mass production |
| Anti-oxidant/anti-wear | ZDDP, aminic and phenolic antioxidants | Engine and industrial oils | Commercial |
| Viscosity-index improvers & industrial specialty components | Full range | Multigrade oils, industrial lubricants | Commercial |
| Additive packages | Engine oil (passenger/HDD incl. China D1 standard), marine, industrial (gear, hydraulic), metalworking, grease, shock-absorber fluid, TO-4/UTTO transmission fluids, 2-stroke UAV engine oil, long-drain axle oil (200,000 km) | OEM and oil-company blenders | Four TO-4/UTTO packages industrialized; UAV 2T oil industrialized; certification of engine/marine/industrial packages ongoing |
Capacity: 133 kt with 50.28% utilization (FY2024); plus 30 kt single-component expansion commissioned January 2025, taking capacity to ~163 kt (FY2024 AR; Shenwan Hongyuan May 2026). Kangtai serves over 3,000 customers in 20+ countries and partners with all four international additive majors (FY2024 AR).
Life sciences
| Line | Products | Status |
|---|---|---|
| Oligonucleotide (small-nucleic-acid drug) raw materials | 2'-TBDMS-rN, 2'-OMe-rN, 2'-MOE-rN, 2'-F-dN and DNA phosphoramidite (CEPA) monomers; modified nucleosides; GalNAc delivery ligands; UnyLinker solid supports | Monomers in stable production (30–35 kg batches for main series); GalNAc at pilot; UnyLinker at pilot scale; 6 t nucleic-acid monomer pilot plant in Tianjin |
| mRNA / IVD / sequencing reagents | NTP, dNTP (incl. proprietary hot-start "Thermal-initiated dNTP Mix" launched 2024), ddNTP for nucleic-acid mass spectrometry | Commercial on order; ~90 customers developed in 2024; 70+ dNTP/ddNTP customers |
| Synthetic biology | Salidroside, astaxanthin, poly-γ-glutamic acid (trial production and trial sales) | Partnerships with Tianjin University, Tianjin University of Science & Technology, CAS Tianjin Institute of Industrial Biotechnology |
| Animal nutrition | Not detailed | Scenario validation; batch supply to large-scale livestock customers planned H2 2026 |
Management expects the bio-building-block business to reach break-even in FY2026 (H1 2026 report). Revenue was CNY 3.63 M in FY2024; FY2025 not separately disclosed in sources reviewed.
Electronic materials (PI and adhesives)
| Product | Description | End-use | Status |
|---|---|---|---|
| YPI (PI varnish for flexible OLED substrates) | Polyimide precursor coated and cured to replace glass in flexible displays | Notebooks, tablets, TVs, foldables | Mass-produced and sold by IPITECH (Korea) |
| FTPI | Thermoplastic PI film for adhesive-less 2-layer FCCL | Smartphones, wearables | Mass-produced in Korea |
| PTPI | Heat-resistant PI tape film for QFN semiconductor packaging (mold-flash protection, residue-free removal) | Semiconductor packaging | Mass-produced in Korea |
| Electronic adhesives | Via 25% stake in Shenzhen Stofor | Electronics assembly | Equity-accounted associate |
China production base and R&D centre in Yixing (budget CNY 400 M; 20.78% of budget spent, project progress 60% at 30 June 2026) targeted to start in 2027 (H1 2026 report). Management stated at its September 2025 results call that its PI products are used in certain smart-glasses brands (36Kr summary). Rianlon describes partnerships with domestic flexible-circuit and flexible-display leaders with qualification "substantive progress" in H1 2026.
Financial Narrative
Income statement: notes and sources
Sources: S&P std. via StockAnalysis (data updated Aug 2026). CAS-reported basic EPS: FY2022 2.3965, FY2023 1.5786, FY2024 1.8566 (FY2024 AR), consistent with the above.
Balance sheet
Sources: S&P std. via StockAnalysis; short/long debt split derived by summing short-term borrowings, current portion of LTD and leases. CAS asset-liability ratio: FY2023 47.89%, FY2024 48.26%, FY2025 52.61%, H1 2026 52.88% (Eastmoney; H1 2026 report).
H1 2026 balance sheet (CAS, 30 June 2026): total assets CNY 10,886.8 M; cash CNY 1,862.6 M (of which CNY 37.7 M restricted, CNY 102.0 M held offshore); short-term borrowings CNY 2,065.0 M; current portion of non-current liabilities CNY 524.4 M; long-term borrowings CNY 487.7 M (down from CNY 1,099.7 M); bonds payable CNY 806.9 M (new sci-tech MTN); construction in progress CNY 617.9 M (Malaysia CNY 435.9 M, PI CNY 83.1 M); goodwill CNY 636.8 M; parent equity CNY 4,986.1 M.
Goodwill composition (CNY M, unchanged FY2024–H1 2026): Lianlong Kaiya 326.83; Jinzhou Kangtai 172.42; Yixing Chuangju 109.98; Lianlong Kerun 26.62; Tianjin Aegis 0.92. No impairment has been booked; goodwill was a Key Audit Matter in the FY2025 audit report.
Cash flow: notes and sources
Note: S&P's "common dividends paid" line (FY2021 93.9 → FY2025 151.3) appears to include interest paid (CAS line "dividends, profits or interest paid"), so declared dividends are shown instead: FY2021 0.306 × 205.01 M shares and FY2022 0.344 × 229.62 M shares are derived; FY2023 CNY 78.99 M, FY2024 CNY 84.96 M and FY2025 CNY 103.33 M are reported (FY2024 AR; H1 2026 report). H1 2026: operating cash flow +CNY 161.6 M vs −CNY 56.3 M in H1 2025; investing −CNY 265.0 M (overseas project); capex (cash paid for long-term assets) CNY 409.9 M vs CNY 98.5 M.
Ratios
Sources: ROE/ROA/ROIC/liquidity/leverage/turnover from S&P std.; CAS ROE from FY2024 AR. Interest coverage, DSO (year-end AR ÷ revenue × 365), DIO (365 ÷ inventory turnover), DPO (year-end AP ÷ cost of revenue × 365) and CCC are derived; S&P AR may include notes receivable, overstating DSO relative to a trade-only measure. H1 2026 CAS interest coverage 11.41x and EBITDA interest coverage 17.60x (H1 2026 report, bond section).
Commentary on trends, inflections and drivers
FY2021–FY2022 — capacity-led boom. Revenue grew ~39–41% annually as new capacity (Zhongwei, Kaiya, Zhuhai) met a post-pandemic polymer demand surge and Kangtai was consolidated from mid-2022. EBITDA margins held near 17–18% and ROIC exceeded 13%. However, cash conversion was already weak: FY2021 free cash flow was −CNY 203 M because capex (CNY 515 M) and a CNY 706 M receivable build absorbed operating cash.
FY2023 — the inflection. Revenue still grew 9% (Kangtai full-year effect), but S&P gross margin collapsed ~450 bp to 19.1% and net income fell 31% to CNY 362 M. Industry sources describe 2023 as the start of "irrational low-price competition" among Chinese anti-aging producers (Guanyan Tianxia, Dec 2025). Newly commissioned Zhuhai and Chifeng capacity added depreciation (D&A up 37%) before reaching scale. FCF was −CNY 401 M as capex peaked at CNY 574 M.
FY2024–FY2025 — volume-led grind back. Net income recovered 17.6% and 16.5% respectively, driven by volume (anti-aging +6% then +12%; lubricants +23% then +15%), mix improvement in light stabilizers, and a sharp turnaround in Kangtai (FY2025 net profit CNY 96 M, +117%, per Shenwan). Zhuhai swung from a CNY 10.4 M loss (FY2024) to a CNY 32 M profit (FY2025). Pricing remained a headwind: average anti-aging price fell ~7% in FY2025. EBITDA margin recovered to 16.3%, but ROIC (8.1%) remains roughly half the 2021 level.
Balance-sheet drift. Total debt more than doubled from CNY 1.48 bn (FY2021) to CNY 3.76 bn (FY2025), and short-term debt rose to CNY 2.66 bn, reflecting funding of working capital (receivables + inventory up from CNY 1.84 bn to CNY 3.30 bn), M&A and the Malaysia pre-funding. Net debt/EBITDA stayed contained (1.7x) only because cash was also built up (CNY 2.1 bn incl. short-term investments). The cash conversion cycle has lengthened from ~84 to ~150 days (derived), the single most important financial-quality concern.
H1 2026. Revenue CNY 3,389.6 M (+13.17%), net income CNY 297.3 M (+23.24%), recurring net income CNY 293.3 M (+24.12%), despite a CNY 77.1 M financial expense (vs −CNY 1.8 M), largely FX-driven (RMB appreciation). Minority interests absorbed a CNY 12.4 M loss (mainly PI). Gross margin improved in both core segments.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Polymer anti-aging additives (CNY Mn) | 4,345.05 | 4,594.16 | 4,774.00 |
— of which Antioxidants (CNY Mn) | 1,601.58 | 1,729.51 | 1,920.00 |
— of which Light stabilizers (CNY Mn) | 1,873.90 | 2,085.86 | 2,075.00 |
— of which U-pack (CNY Mn) | 637.86 | 613.80 | 596.00 |
Lubricant additives (CNY Mn) | 921.71 | 1,063.64 | 1,207.00 |
Life sciences (CNY Mn) | 0.80 | 3.63 | — |
Other incl. other business revenue (CNY Mn) | 10.89 | 25.48 | — |
Total revenue (CNY Mn) | 5,278.46 | 5,686.92 | 6,023.00 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Anti-aging revenue YoY growth (%) | — | 5.73 | 3.92 |
Lubricant revenue YoY growth (%) | — | 15.40 | 13.51 |
Anti-aging share of total revenue (%) | 82.32 | 80.78 | 79.26 |
Lubricant share of total revenue (%) | 17.46 | 18.70 | 20.04 |
Anti-aging gross margin (%) | 21.59 | 23.78 | 24.36 |
Lubricant gross margin (%) | 11.85 | 9.95 | 14.12 |
Anti-aging gross profit (CNY Mn) | 938 | 1,093 | 1,163 |
Lubricant gross profit (CNY Mn) | 109 | 106 | 170 |
Product Line FY2024 Details
| Product line FY2024 | Revenue (CNY Mn) | Cost (CNY Mn) | Gross margin (%) | Revenue YoY (%) | GM change (pp) |
|---|---|---|---|---|---|
Antioxidants | 1,729.51 | 1,394.34 | 19.38 | 7.99 | 2.28 |
Light stabilizers | 2,085.86 | 1,393.34 | 33.20 | 11.31 | 1.25 |
U-pack | 613.80 | 562.49 | 8.36 | -3.77 | 1.20 |
Lubricant additives | 1,063.64 | 957.79 | 9.95 | 15.40 | -1.90 |
Operating Metrics (kt) and Share Price
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Anti-aging sales volume (kt) | 116.17 | 123.61 | 138.00 |
Lubricant sales volume (kt) | 47.33 | 58.32 | 67.10 |
Anti-aging average price (CNY/t) | 37,402 | 37,167 | 34,602 |
Lubricant average price (CNY/t) | 19,474 | 18,237 | 17,989 |
Segment Revenue
| Segment | H1 2026 revenue (CNY Mn) | YoY (%) | H1 2026 GM (%) | GM change (pp) | Volume (kt) | Volume YoY (%) |
|---|---|---|---|---|---|---|
Polymer anti-aging additives | 2,655.61 | 12.64 | 25.86 | 2.21 | 77.2 | 17.81 |
Lubricant additives | 706.74 | 14.27 | 15.67 | 2.19 | 35.8 | 4.78 |
Group Entities
| Subsidiary | Role | FY2024 revenue (CNY Mn) | FY2024 net profit (CNY Mn) | H1 2026 revenue (CNY Mn) | H1 2026 net profit (CNY Mn) |
|---|---|---|---|---|---|
Rianlon (Zhongwei) New Materials — Ningxia | Antioxidants/light stabilizers/U-pack; captive heat | 1,045.85 | 182.27 | 557.40 | 74.95 |
Rianlon Technology Co. — Hong Kong | International trading hub | 2,195.98 | 59.12 | 1,587.40 | 71.09 |
Lianlong Kaiya (Hebei) — Hengshui | Light stabilizers, intermediates, inhibitors | 1,051.79 | 150.33 | 456.79 | 67.13 |
Lianlong Kerun (Zhejiang) — Changshan | Light stabilizers | 254.15 | 26.03 | 139.17 | 21.12 |
Rianlon (Zhuhai) New Materials | Antioxidants, U-pack, liquid additives | 926.53 | -10.39 | 687.67 | 60.15 |
Rianlon Supply Chain Management | Domestic trading/logistics | 2,217.27 | -9.27 | 1,210.85 | 10.96 |
Suzhou Rianlon New Materials | East China sales/technical service | 0.48 | -9.05 | 131.75 | -2.97 |
Jinzhou Kangtai Lubricant Additives | Lubricant additives | 1,083.02 | 44.06 | 740.06 | 60.50 |
Rianlon (Inner Mongolia) — Chifeng | Light stabilizers and intermediates | 225.81 | 0.63 | 116.16 | 2.01 |
Yixing Chuangju Electronic Materials (51.18%) | PI holding company; owns IPITECH (Korea) | 7.16 | -17.31 | 4.67 | -13.91 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 3,445 | 4,843 | 5,278 | 5,687 | 6,023 |
Revenue growth YoY (%) | 38.74 | 40.59 | 9.00 | 7.74 | 5.91 |
Gross profit (CNY Mn) | 904.51 | 1,144 | 1,008 | 1,150 | 1,274 |
SG&A (CNY Mn) | 230.19 | 294.49 | 322.18 | 397.40 | 404.27 |
R&D expense (CNY Mn) | 151.30 | 208.35 | 233.44 | 247.20 | 253.22 |
Operating income / EBIT (CNY Mn) | 501.61 | 616.79 | 420.33 | 475.66 | 593.17 |
D&A (CNY Mn) | 131.61 | 207.39 | 283.57 | 345.53 | 387.05 |
EBITDA (CNY Mn) | 633.21 | 824.18 | 703.90 | 821.19 | 980.22 |
Interest expense (CNY Mn) | 28.37 | 44.94 | 60.83 | 63.40 | 63.98 |
FX gain/(loss) (CNY Mn) | -18.26 | -5.93 | 12.06 | 14.42 | -10.74 |
Pre-tax income (CNY Mn) | 476.36 | 581.83 | 408.12 | 470.68 | 543.69 |
Income tax (CNY Mn) | 50.18 | 55.99 | 50.60 | 56.48 | 70.24 |
Effective tax rate (%) | 10.53 | 9.62 | 12.40 | 12.00 | 12.92 |
Net income attributable (CNY Mn) | 417.59 | 525.72 | 362.49 | 426.32 | 496.56 |
Basic EPS (CNY) | 2.04 | 2.40 | 1.58 | 1.86 | 2.16 |
Diluted EPS (CNY) | 2.04 | 2.40 | 1.58 | 1.86 | 2.16 |
Dividend per share declared (CNY) | 0.306 | 0.344 | 0.344 | 0.370 | 0.450 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin S&P std. (%) | 26.26 | 23.62 | 19.10 | 20.23 | 21.15 |
Gross margin company-reported CAS (%) | — | 24.26 | 19.78 | 21.24 | 22.33 |
Operating (EBIT) margin (%) | 14.56 | 12.74 | 7.96 | 8.36 | 9.85 |
EBITDA margin (%) | 18.38 | 17.02 | 13.33 | 14.44 | 16.28 |
Net margin (%) | 12.12 | 10.86 | 6.87 | 7.50 | 8.24 |
Revenue CAGR from FY2021 (%) | 0 | 40.59 | 23.77 | 18.17 | 14.99 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 5,578 | 7,583 | 8,214 | 9,134 | 10,517 |
Cash & equivalents (CNY Mn) | 467.88 | 819.36 | 946.75 | 1,068 | 1,994 |
Cash + short-term investments (CNY Mn) | 467.88 | 859.37 | 1,040 | 1,230 | 2,100 |
Accounts receivable (CNY Mn) | 946.36 | 1,141 | 1,417 | 1,629 | 1,937 |
Inventory (CNY Mn) | 893.07 | 1,282 | 1,142 | 1,330 | 1,362 |
Net PP&E (CNY Mn) | 2,427 | 3,166 | 3,445 | 3,581 | 3,645 |
Goodwill (CNY Mn) | 353.45 | 525.87 | 525.87 | 636.78 | 636.78 |
Other intangibles (CNY Mn) | 227.57 | 305.37 | 352.83 | 426.54 | 394.41 |
Short-term debt incl. current LTD and leases (CNY Mn) | 741.85 | 688.48 | 1,054.01 | 1,220.86 | 2,656.18 |
Long-term debt incl. leases (CNY Mn) | 735.08 | 1,103.06 | 1,179.13 | 1,477.01 | 1,100.68 |
Total debt (CNY Mn) | 1,477 | 1,792 | 2,233 | 2,698 | 3,756 |
Net debt (CNY Mn) | 1,009 | 932.53 | 1,193 | 1,468 | 1,656 |
Total equity incl. minorities (CNY Mn) | 2,626 | 3,928 | 4,280 | 4,726 | 4,984 |
Equity attributable to parent (CNY Mn) | 2,521 | 3,817 | 4,107 | 4,459 | 4,827 |
Working capital (CNY Mn) | 288.08 | 959.07 | 1,059 | 1,531 | 1,308 |
Book value per share (CNY) | 12.30 | 16.62 | 17.89 | 19.42 | 21.02 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 312.13 | 513.85 | 172.63 | 463.61 | 378.21 |
Capital expenditure (CNY Mn) | 514.98 | 292.83 | 573.67 | 254.67 | 242.36 |
Free cash flow (CNY Mn) | -202.86 | 221.02 | -401.04 | 208.94 | 135.85 |
Change in working capital (CNY Mn) | -326.84 | -336.17 | -576.63 | -437.04 | -612.96 |
Cash acquisitions (CNY Mn) | 3.19 | 170.17 | 0 | 191.85 | 0 |
Cash dividends declared for the fiscal year (CNY Mn) | 62.73 | 78.99 | 78.99 | 84.96 | 103.33 |
Share buybacks (CNY Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt issued/(repaid) (CNY Mn) | 624.75 | 43.21 | 663.89 | 136.15 | 1,058 |
Equity issued (CNY Mn) | 3.00 | 423.90 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 17.73 | 16.05 | 8.71 | 9.20 | 9.75 |
Weighted-average ROE, CAS (%) | — | 16.29 | 9.15 | 9.95 | — |
ROA (%) | 6.68 | 5.86 | 3.33 | 3.43 | 3.77 |
ROIC (%) | 13.98 | 13.12 | 7.13 | 7.17 | 8.05 |
Current ratio (x) | 1.13 | 1.39 | 1.40 | 1.54 | 1.30 |
Quick ratio (x) | 0.67 | 0.82 | 0.92 | 1.02 | 0.94 |
Debt / equity (x) | 0.56 | 0.46 | 0.52 | 0.57 | 0.75 |
Net debt / EBITDA (x) | 1.59 | 1.13 | 1.70 | 1.79 | 1.69 |
EBIT interest coverage (x) | 17.68 | 13.72 | 6.91 | 7.50 | 9.27 |
Asset turnover (x) | 0.73 | 0.74 | 0.67 | 0.66 | 0.61 |
Inventory turnover (x) | 3.53 | 3.40 | 3.52 | 3.67 | 3.53 |
Days sales outstanding (days) | 100 | 86 | 98 | 105 | 117 |
Days inventory outstanding (days) | 103 | 107 | 104 | 99 | 103 |
Days payables outstanding (days) | 100 | 109 | 79 | 73 | 70 |
Cash conversion cycle (days) | 103 | 84 | 123 | 131 | 150 |
Revenue History
| Quarter | Revenue (CNY Mn) | Net income attributable (CNY Mn) | Source |
|---|---|---|---|
Q1 2024 | 1,354.26 | 107.14 | FY2024 AR |
Q2 2024 | 1,465.68 | 112.98 | FY2024 AR |
Q3 2024 | 1,445.18 | 93.83 | FY2024 AR |
Q4 2024 | 1,421.79 | 112.37 | FY2024 AR |
Q1 2025 | 1,481 | 108 | Derived from Q1 2026 YoY rates (Shenwan) |
Q2 2025 | 1,514 | 133 | Derived (H1 2025 total 2,995.0 / 241.3 less Q1) |
Q3 2025 | 1,514 | 151 | Derived (FY less H1 less Q4) |
Q4 2025 | 1,514 | 104 | Shenwan Hongyuan (May 2026) |
Q1 2026 | 1,592 | 132 | Shenwan Hongyuan (May 2026) |
Q2 2026 | 1,797 | 165 | Southwest Securities (Aug 2026) |
Revenue by Region and Revenue by Region (%)
| Region | FY2023 | FY2024 |
|---|---|---|
Domestic China revenue (CNY Mn) | 3,328.58 | 3,323.46 |
Overseas revenue (CNY Mn) | 1,949.88 | 2,363.46 |
Overseas share of revenue (%) | 36.94 | 41.56 |
Domestic gross margin (%) | 15.55 | 16.91 |
Overseas gross margin (%) | 27.01 | 27.33 |
Region Overview
| Region | FY2024 YoY growth (%) |
|---|---|
Domestic China | -0.15 |
Overseas | 21.21 |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (CNY) | 42.53 | 52.21 | 28.53 | 29.81 | 41.80 |
Year-end market capitalization (CNY Mn) | 9,176 | 12,530 | 6,788 | 7,003 | 9,692 |
Market cap change YoY (%) | 13.95 | 36.55 | -45.83 | 3.18 | 38.39 |
Valuation Multiples
| Multiple | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
P/E (x) | 21.97 | 23.84 | 18.73 | 16.43 | 19.52 |
EV/EBITDA (x) | 16.25 | 16.41 | 11.61 | 10.73 | 11.71 |
EV/Sales (x) | 2.99 | 2.79 | 1.55 | 1.55 | 1.91 |
P/B (x) | 3.49 | 3.19 | 1.59 | 1.48 | 1.95 |
Dividend yield (%) | 0.72 | 0.66 | 1.21 | 1.24 | 1.08 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price (CNY) | 2026E revenue (CNY Mn) | 2026E NI (CNY Mn) | 2027E NI (CNY Mn) | 2028E NI (CNY Mn) |
|---|---|---|---|---|---|---|---|
Kaiyuan Securities | 18 Aug 2026 | Buy (maintained) | — | 7,029 | 657 | 743 | 827 |
Southwest Securities | 31 Aug 2026 | Buy (initiation) | 57.33 | 6,613 | 627 | 742 | 941 |
Orient Securities | 30 Apr 2026 | Buy (maintained) | 50.16 | — | EPS 2.64 | EPS 3.09 | EPS 3.51 |
Shenwan Hongyuan | 4 May 2026 | n/d in excerpt | — | — | — | — | — |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
DPS (CNY) | 0.306 | 0.344 | 0.344 | 0.370 | 0.450 |
Total cash dividend (CNY Mn) | 62.73 | 78.99 | 78.99 | 84.96 | 103.33 |
Payout of attributable NI (%) | 15.0 | 15.0 | 21.8 | 19.9 | 20.8 |
Debt Maturity Profile
| Maturity bucket (30 Jun 2026) | Amount (CNY Mn) |
|---|---|
Short-term borrowings (≤1 yr) | 2,065.0 |
Current portion of non-current liabilities (≤1 yr) | 524.4 |
Long-term bank borrowings (>1 yr) | 487.7 |
Bonds payable (2029) | 806.9 |
Lease liabilities (>1 yr) | 0.6 |
Analyst Conclusions
Management guidance
No numeric FY2026 guidance. Qualitative signals from the H1 2026 report: continued volume growth in both core businesses; bio-building blocks to break even in 2026; animal-nutrition batch supply in H2 2026; Yixing PI capacity in 2027; Malaysia Phase I under construction (60% progress). Long-term 2028 divisional targets (CNY 10 bn / 4 bn / 1 bn) are aspirational.
Consensus expectations
Broker forecasts imply FY2026 revenue of CNY 6.6–7.0 bn (+10–17%) and attributable NI of CNY 627–657 M (+26–32%), with 2027–2028 NI growth of 12–27% annually (Kaiyuan; Southwest; Orient). H1 2026 delivered 49% of the low-end full-year NI forecast, so H2 needs ~CNY 330–360 M — consistent with Q2 2026's CNY 165 M run-rate plus modest growth.
Bull case
-
Global supply rebalancing: BASF's 2026 price increases and European capacity attrition allow Rianlon to raise anti-aging prices while volume grows ~15%+, restoring EBIT margins toward 12%+ (FY2022 level 12.7%).
-
Lubricants as a real second engine: Kangtai's FY2025 profit more than doubled; the Infineum alliance and D1 standard could lift utilization of 163 kt capacity and push GM toward the high teens.
-
Valuation: ~14x 2026E earnings and 1.76x book, below broker peer multiples of 19–21x; a re-rating to 19x on ~CNY 2.8 EPS implies ~CNY 53, near broker targets (CNY 50–57).
Bear case
-
Cash conversion and leverage: five-year cumulative FCF is negative while debt has risen ~2.5x; Malaysia (≤USD 300 M) and Yixing (CNY 400 M) capex will keep FCF thin through 2027.
-
Persistent domestic deflation: anti-aging ASP fell 7% in FY2025 and ~4% in H1 2026; if Western price increases fade, margins could stall.
-
Governance and overhang: combined Chair/President, ~50% pledge ratio at the Group, a potential 3% controller sale, and related-party sourcing may cap multiples.
Key catalysts and monitorables (next 12 months)
-
Q3 2026 results (late October 2026): gross-margin trend, FX losses, receivable build.
-
Execution and timing of the controller's share-sale plan; pledge ratio.
-
Johor Phase I construction progress and commissioning date; customer qualification.
-
Tangible volumes under the Infineum agreement (any disclosure of contract size).
-
BASF/SONGWON pricing actions and Chinese anti-involution enforcement.
-
Kangtai package certifications (D1, marine, industrial).
-
PI qualification wins with display/FPC leaders; Yixing start-up in 2027; Chuangju losses.
-
Goodwill impairment testing at FY2026 year-end.
-
FY2026 dividend (payout trend ~20%).
Analyst verdict
Rianlon is a credible, internationally competitive Chinese specialty-additives champion emerging from a three-year margin trough, but it is not yet a high-quality compounder. The core polymer anti-aging franchise has the breadth, redundancy and export relationships to gain share as Western producers retrench, and 2026 has so far validated that thesis: H1 revenue grew 13% and recurring profit 24%, with margins up in both main segments despite FX headwinds. The lubricant-additive acquisition, initially dilutive to margins, has turned into a genuine second earnings stream, and the January 2026 alliance with Infineum is the most important third-party endorsement in the company's history.
Against this, the financial architecture has deteriorated. Over FY2021–FY2025, Rianlon converted essentially none of its CNY 2.2 bn of cumulative net profit into free cash flow, while total debt rose to CNY 3.8 bn and the cash conversion cycle lengthened materially. The next two years add a heavy capex cycle (Johor and Yixing) and several loss-making options (PI, life sciences, adhesives) whose payoffs are distant. Governance — a combined chair/president, a controller pledging half his holding company's stake and a possible 3% sale — limits the multiple investors will pay.
On balance, the shares at ~CNY 39 (≈14x consensus 2026E, ~10x EV/EBITDA, 1.8x book) discount a meaningful part of the risk while embedding modest expectations for the pricing upturn. The thesis would break on renewed domestic price declines, slippage in Malaysia, or evidence that working-capital growth reflects deteriorating customer credit rather than export mix. Monitor Q3 2026 cash flow closely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / key dates | Background | Age (FY2024 AR) | FY2024 total pre-tax compensation (CNY 10k) |
|---|---|---|---|---|---|
Li Haiping (李海平) "Henry Li" | Chairman (since 2003); President (since Jul 2022); actual controller; re-elected chairman 13 Jun 2025 | 2003– | Graduate degree, chemical engineering; Tianjin University faculty 1986–2013; ran Tianda Tianhai and Rianlon (Tianjin) Industrial; heads Rianlon Technology Group and Rianlon International | 62 | 121.28 |
Fan Xiaopeng (范小鹏) | Director; legal representative (per H1 2026 report); Technical Director, New Materials Division | Joined 2010; employee supervisor 2018–2025 | PhD, chemical engineering; former R&D manager and QC director; chairman of Rianlon (Zhongwei) | 43 | 75.15 |
Sun Chunguang (孙春光) | Vice President | GM 2003–Jul 2022; VP since Jul 2022 | Graduate, senior engineer; Tianjin University faculty; chairman of Zhuhai, Aurif, Aolif | 63 | 113.35 |
Xie Jintao (谢金桃) | VP (finance), Board Secretary | Joined 1998; board secretary since Mar 2021 | Bachelor's, accounting; former CFO | 50 | 89.25 |
Yan Wenjia (阎文嘉) | CFO and chief accounting officer | Since 23 Aug 2023 | Senior accountant; ex-CFO Tianjin Changrong Technology equipment segment, ex-CFO/board secretary TCL Huanxin Semiconductor | 44 | 70.03 |
Ye Qiang (叶强) | Vice President | VP since 13 Jun 2025 (earlier VP 2015–2022, supervisor 2022–2025) | Chemical machinery; ex-Fushun Petrochemical, Shanghai Albemarle, SI Group (Shanghai) | 56 | 117.36 |
Ding Huan (丁欢) | Employee-representative director; audit and nomination committee member | Since 13 Jun 2025 (supervisory board chair 2022–2025) | Foreign languages; strategic cooperation director | 41 | 108.46 |
Bi Hongyan (毕红艳) | Director (status on 5th board n/d) | Joined 2003 | Sales; China marketing director; GM of Supply Chain subsidiary | 49 | 100.81 |
Bi Zuopeng (毕作鹏) | Director, 4th board; Kangtai director & manager | 2018–2025 (5th board status n/d) | Tianjin University faculty | 62 | 97.29 |
Sun Aitian (孙艾田) | Director & VP, 4th board; executive partner of Juxinlong (ESOP vehicle) | 2018–2025 (5th board status n/d) | Tianjin University MBA | 60 | 114.28 |
Han Borui (韩伯睿) | Director & VP, 4th board (departed; locked shares released 12 Jan 2026 as "departed executive") | 2019–2025 | Ex-GM Lianlong Kaiya | 63 | 121.97 |
Governance Overview
| Item | FY2024 (4th board) | 5th board (from 13 Jun 2025) |
|---|---|---|
Board size | 11 (7 non-independent, 4 independent) | — |
Independent directors | Wei Lixing (lubricants industry veteran), Li Hongmei (Central South University accounting academic; audit chair), Hou Weiman (lawyer, Hairun Tianrui; remuneration chair), He Yongjun (Beiyang Haitang VC; nomination chair) | — |
Committees | Strategy; Remuneration & Appraisal; Nomination; Audit & Risk Control | Strategy committee chaired by Li Haiping; audit and nomination committees include employee director Ding Huan |
Supervisory board | 3 members (Ding Huan chair, Ye Qiang, Fan Xiaopeng) | Apparently abolished (former supervisors now director/VP), consistent with 2024 Company Law reforms — not confirmed by an announcement reviewed |
Chair/CEO separation | No — Li Haiping is both Chairman and President | No |
Board meetings FY2024 | 6, all directors attended in person | — |
Major Shareholders
| Rank | Shareholder | Type | Shares | Stake (%) | Pledged shares |
|---|---|---|---|---|---|
| 1 | Tianjin Rianlon Technology Group Co., Ltd. | Controlling shareholder (Li Haiping) | 32,461,290 | 14.14 | 13,237,100 |
| 2 | Rianlon International Group Ltd. | Controlling shareholder, offshore, concert party | 25,059,240 | 10.91 | 0 |
| 3 | Tianjin Juxinlong Equity Investment Fund LP | Employee/management vehicle (Sun Aitian GP) | 15,784,409 | 6.87 | 1,330,000 |
| 4 | Tianjin Shengjinlong Enterprise Management LP | Employee/management vehicle (Xie Jintao GP) | 6,244,556 | 2.72 | 0 |
| 5 | Han Borui | Individual (ex-director) | 6,069,576 | 2.64 | 0 |
| 6 | Bank of Communications – Penghua China 50 Fund | Mutual fund | 5,561,799 | 2.42 | 0 |
| 7 | Hong Kong Securities Clearing Co. | Northbound Stock Connect | 5,279,364 | 2.30 | 0 |
| 8 | Han Houyi | Individual (Kaiya vendor) | 4,156,800 | 1.81 | 0 |
| 9 | Sequoia Jincheng (Xiamen) Equity Investment LP | PE | 3,339,767 | 1.45 | 0 |
| 10 | Han Qian | Individual (Kangtai vendor) | 1,998,990 | 0.87 | 0 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Country | Positioning vs. Rianlon |
|---|---|---|---|
Polymer anti-aging | BASF (Irganox/Tinuvin/Chimassorb) | Germany | Global leader and price-setter; only other full-range supplier; raised prices twice since Mar 2026 |
Polymer anti-aging | SONGWON Industrial | Korea | Self-described #2 polymer stabilizer producer globally; FY2025 sales KRW 1,039.2 bn, GM 13.7% |
Polymer anti-aging | SI Group | USA | Antioxidants/phosphites |
Polymer anti-aging | Clariant | Switzerland | Additives (HALS, Hostavin) |
Polymer anti-aging | ADEKA | Japan | Antioxidants, nucleators |
Polymer anti-aging | Everspring Chemical | Taiwan | UVAs/HALS |
Polymer anti-aging | Suqian Unitech (宿迁联盛) | China | HALS/antioxidants; cited as a domestic price-war participant |
Polymer anti-aging | Yingkou Fengguang (风光股份) | China | Phenolic and phosphite antioxidants; FY2025 revenue CNY 1,141 M, net loss CNY 48.6 M |
Lubricant additives | Lubrizol, Infineum, Chevron Oronite, Afton (NewMarket) | US/UK | ~80–85% global share; Infineum now a partner |
Lubricant additives | Richful Advanced Materials (瑞丰新材) | China | Largest listed domestic lubricant-additive peer; 9M2024 revenue CNY 2,301 M, NI CNY 500 M, GM 36.1% |
Lubricant additives | Wuxi South Petroleum Additives | China | Third scaled private domestic player |
Electronic PI | DuPont, UBE, Kaneka, PI Advanced Materials (PIAM) | US/Japan/Korea |
|
Peer Comparison FY2025
| Metric | Rianlon FY2025 | SONGWON FY2025 | Yingkou Fengguang FY2025 | Richful (lubricant peer) 9M FY2024 |
|---|---|---|---|---|
Revenue (native) | CNY 6,023 M | KRW 1,039,162 M | CNY 1,141 M | CNY 2,301 M (9M) |
Revenue growth (%) | 5.91 | — | 13.66 | 6.89 |
Gross margin (%) | 22.33 | 13.7 | — | 36.08 |
Net income (native) | CNY 497 M | — | CNY −48.6 M | CNY 500 M (9M) |
R&D intensity (%) | 4.20 | — | — | — |



